Caption Management LLC Grows Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Caption Management LLC lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 1,112.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 150,338 shares of the company's stock after buying an additional 137,938 shares during the period. Caption Management LLC's holdings in Roivant Sciences were worth $1,778,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after acquiring an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in Roivant Sciences during the 4th quarter valued at about $39,000. GAMMA Investing LLC raised its position in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after purchasing an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after purchasing an additional 1,507 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Roivant Sciences by 84.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after buying an additional 3,426 shares during the period. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock traded down $0.38 during trading on Friday, hitting $10.65. The company's stock had a trading volume of 6,735,679 shares, compared to its average volume of 5,554,372. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The company has a fifty day simple moving average of $10.49 and a two-hundred day simple moving average of $11.11. The company has a market capitalization of $7.60 billion, a PE ratio of -71.00 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Insider Activity

In related news, major shareholder Vivek Ramaswamy sold 273,959 shares of the stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the sale, the insider now directly owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This represents a 0.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the transaction, the chief operating officer now directly owns 896,869 shares in the company, valued at $9,551,654.85. This represents a 10.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,669,500 shares of company stock valued at $18,064,847 in the last ninety days. 7.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ROIV shares. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.